Author

Kevin Li

UC San Diego Health SystemORCID 0000-0002-6790-0180Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Kevin Li2 papers · Duke University

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Organism:mouse· 1

Frequent Co-Authors

Alexei MartsinkovskiyiD· 1 shared Andrew M. LowyiD· 1 shared Asimina S. CourelliiD· 1 shared Evangeline Sari. MoseiD· 1 shared Hervé TiriaciD· 1 shared Isabella NgiD· 1 shared James LeeiD· 1 shared Jay PateliD· 1 shared

Activity by Year

2024-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alexei MartsinkovskiyORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

SUMO Inhibition Plus CD40 Agonism Increases Anti-Tumor Immunogenicity Through Interferon Mediated Macrophage Activation

Kevin Li, Asimina S. Courelli, James Lee, Tatiana Hurtado de Mendoza, Alexei Martsinkovskiy, Evangeline Sari. Mose, Jay Patel, Isabella Ng, Siming Sun, M.D. Neranjan Tharuka, Hervé Tiriac, Yuan Chen, Andrew M. Lowy

This study shows that combining SUMO inhibition with CD40 agonism enhances anti-tumor immunogenicity in PDAC by improving macrophage function and T-cell infiltration, leading to improved survival in a mouse model.

bioRxiv · Dec 3, 2024 · PreprintCancer Biology